CCR2 and cancer: The results indicated that TMEM240 decreased the expression levels of fibroblast growth Factor 2 (FGF2), stromal cell-derived factor-1 (SDF-1), vav guanine nucleotide exchange Factor 1 (VAV-1), C–C motif chemokine receptor 2 (CCR2), nuclear factor-κB (NF-kB), oncostatin M, and matrix metalloproteinase-2 (MMP2), which stimulate cell proliferation, migration, and the cancer epithelial–mesenchymal transition (EMT) process, and increased the expression levels of E-cadherin (CDH1) and vascular endothelial (VE)-cadherin, which inhibit cell migration (Additional file 1: Figs. S5 and S6).